drugset
drugset / Trial / NCT05660720

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

NCT05660720 ↗

Phase 1 Unknown 48 enrolled Beijing InnoCare Pharma Tech Co., Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This is A Randomized, Blinded, Placebo- and Positive-Controlled, Four-Period, Crossover-Design Thorough QT/QTc (TQT) Study to Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Timeline

Start
2022-11-19
Primary completion
2023-06-30
Completion
2023-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg —
Subject Orelabrutinib Small molecule 150 mg —
Subject Orelabrutinib Small molecule 400 mg —

Indications

No indication recorded.